- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06133322
Strategie di abbassamento della pressione sanguigna per eliminare le disparità di ipertensione (BENEDETTO) (BLESSED)
Strategie di abbassamento della pressione sanguigna per eliminare le disparità di ipertensione
The burden of hypertension and related cardiovascular diseases, stroke, and end-stage kidney disease is disproportionately high in Black populations, especially in the South. The Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED) cluster randomized trial aims to test the effectiveness, implementation, and sustainability of a community health worker (CHW)-led multifaceted intervention compared to enhanced usual care for hypertension control in Black communities. In the BLESSED trial, the investigators plan to recruit 1,176 adults with hypertension (approximately 28 per church) from 42 predominantly Black churches in the Greater New Orleans area. The multifaceted intervention will last for 18 months, followed by a post-intervention follow-up visit at 24 months. The BLESSED trial aims to generate evidence regarding the effectiveness, implementation, and sustainability of this CHW-led church-based multifaceted intervention in eliminating hypertension disparities in the United States (US) general population.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Louisiana residents, especially African Americans, bear a disproportionately high burden of hypertension and cardiovascular disease (CVD). In the Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED) cluster randomized trial, the investigators will compare the impact of two implementation strategies - a CHW-led multifaceted strategy and a group-based education strategy - for delivering interventions recommended by the 2017 American College of Cardiology (ACC) and the American Heart Association (AHA) hypertension clinical guidelines on implementation and clinical effectiveness outcomes in predominantly Black community members over 18 months. The BLESSED study utilizes an effectiveness-implementation hybrid design to: (1). test the effectiveness of a CHW-led church-based multifaceted implementation strategy for reducing estimated CVD risk over 18 months among African American church community members at high risk for CVD, and (2). assess the implementation outcomes (acceptability, adaptation, adoption, feasibility, fidelity, penetrance, cost-effectiveness, and sustainability) simultaneously. The Exploration, Preparation, Implementation, Sustainment (EPIS) framework has guided the development and evaluation of the multifaceted implementation strategy, which includes CHW-led health coaching on lifestyle changes and medication adherence; healthcare delivery in community; church-based exercise and weight loss programs; self-monitoring of blood pressure (BP); and provider education and engagement. The CHW-led church-based intervention will provide strong social support and tackle multiple social determinants of CVD disparities. The primary clinical effectiveness outcome is the difference in mean change of systolic blood pressure (SBP) from baseline to 18 months between intervention and control groups. The primary implementation outcome is a fidelity summary score for key implementation strategy components to the CHW-led church-based multifaceted implementation strategy assessed at the participant levels. This study has 90% statistical power to detect group differences in mean SBP change of 5.8 mm Hg over 18 months using a 2-sided significance level of 0.05. The investigators will recruit 1,176 participants (28 per church) who are aged ≥18 years with systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mm Hg, and randomly assign 21 churches to intervention and 21 to control; the investigators will implement the multifaceted intervention program; the investigators will follow-up participants and collect data on effectiveness and implementation outcomes at 6, 12, and 18 months; the investigators will evaluate the sustainability of the intervention at 6 months post-intervention; and the investigators will perform intention-to-treat analyses and disseminate and scale-up the proven-effective implementation strategy. The proposed study will generate evidence on the effectiveness, implementation, and sustainability of the multifaceted intervention aimed at eliminating CVD disparities in African American populations in the US.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Louisiana
-
New Orleans, Louisiana, Stati Uniti, 70112
- Reclutamento
- Tulane University
-
Contatto:
- Jodie Laurent, MPH
- Numero di telefono: 504-988-5432
- Email: jlaurent@tulane.edu
-
Contatto:
- Allison N Marshall, PhD MPH MSSW
- Numero di telefono: 5049886454
- Email: amarshall@tulane.edu
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Men or women aged ≥18 years
- Community members associated with the participating churches (church members and their families and friends)
- Systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mm Hg
- Willing and able to participate in the intervention.
- Willing and able to sign written informed consent.
Exclusion Criteria:
- Prior hospitalization in the last 3 months for chronic heart failure or heart attack
- Current diagnosis of cancer requiring chemotherapy or radiation therapy
- Stage-5 chronic kidney disease requiring chronic dialysis or transplant
- Pregnant or planning to become pregnant in the next 18 months
- Planning to move out of the Greater New Orleans area during the next year
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Community health worker-led implementation strategy
CHW-led church-based multifaceted implementation strategy: CHWs will conduct individualized health coaching and healthcare navigation, organize church-based health promotion programs (e.g., nutrition education and exercise sessions), and train and assist the study participants in self-monitoring of BP. Nurse practitioners will see study participants at church settings, and community pharmacies will deliver antihypertensive medications to patients' homes. |
The recommended evidence-based interventions include therapeutic lifestyle change and medical treatment of hypertension |
|
Sperimentale: Group-based Education Strategy
The investigator team will work with church leadership and wellness coordinators to organize group-based education sessions. Health education will be delivered by local primary care providers, dieticians, and health educators. Contact information for primary care providers and information on self-monitoring of BP will also be given at group sessions. |
The recommended evidence-based interventions include therapeutic lifestyle change and medical treatment of hypertension |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Difference in mean change of systolic blood pressure
Lasso di tempo: Measured from baseline to 18 months
|
Difference in mean change of systolic blood pressure from baseline to 18 months between intervention and control groups |
Measured from baseline to 18 months
|
|
Implementation fidelity summary score
Lasso di tempo: Measured at 6, 12, and 18 months
|
The fidelity summary score is composed of the following key implementation strategy components: proportion of assigned health education sessions attended in all participants, proportion of assigned discussion sessions attended in all participants, proportion of recommended minutes of physical activity completed in all participants, proportion of days per week that fruits/vegetables are eaten as recommended in all participants, proportion of recommended home blood pressure (BP) monitoring completed in patients with hypertension, proportion of required provider visits attended in all patients, and proportion of antihypertensive medications taken in patients with hypertension. The score ranged from zero to six with a higher score indicates greater fidelity. |
Measured at 6, 12, and 18 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Difference in the proportion of patients with controlled BP between intervention and control groups
Lasso di tempo: Measured from baseline to 18 months
|
Difference in the proportion of patients with controlled BP (<130/80 mm Hg) between intervention and control groups at 18 months |
Measured from baseline to 18 months
|
|
Difference in mean change of diastolic BP
Lasso di tempo: Measured from baseline to 18 months
|
Difference in mean change of diastolic BP (DBP) from baseline to 18 months between intervention and control groups |
Measured from baseline to 18 months
|
|
Side effects of medications and adverse events
Lasso di tempo: Measured from baseline to 18 months
|
Change in side effects of medications and adverse events from baseline to 18 months |
Measured from baseline to 18 months
|
|
Cost-effectiveness
Lasso di tempo: Measured from baseline to 18 months
|
Cost-effectiveness assessed as incremental direct costs per additional percentage of hypertension control |
Measured from baseline to 18 months
|
|
Acceptability
Lasso di tempo: Measured from baseline to 18 months
|
Percentage of participants, community health worker, providers, and church administrators who reply that the intervention is acceptable (satisfactory). Measured by survey. |
Measured from baseline to 18 months
|
|
Adoption (Churches)
Lasso di tempo: Measured from baseline to 18 months
|
% of churches adopting the intervention program |
Measured from baseline to 18 months
|
|
Adoption (Providers)
Lasso di tempo: Measured from baseline to 18 months
|
% of invited providers attending training sessions |
Measured from baseline to 18 months
|
|
Appropriateness
Lasso di tempo: Measured from baseline to 18 months
|
Percentage of participants, community health workers, providers, and church administrators who reply that the intervention is appropriate (good perceived fit). The outcome will be measured by survey question. |
Measured from baseline to 18 months
|
|
Feasibility to participant, community health worker, provider and churches
Lasso di tempo: Measured from baseline to 18 months
|
Percentage of participants, community health worker, providers, and church administrators who reply that the intervention is feasible (actual fit, suitability). Measured by survey and study administrative data. |
Measured from baseline to 18 months
|
|
Exercise Session Fidelity (community health worker-led strategy group)
Lasso di tempo: Measured at 6, 12, and 18 months
|
Percentage of exercise sessions organized. Measured by study administrative data. |
Measured at 6, 12, and 18 months
|
|
Fidelity of Group Health Education Session
Lasso di tempo: Measured at 6, 12, and 18 months
|
Percentage of group health education sessions conducted out of health educated sessions planned per study protocol. |
Measured at 6, 12, and 18 months
|
|
Nutrition Education Session Fidelity (community health worker-led strategy group)
Lasso di tempo: Measured at 6, 12, and 18 months
|
Percentage of nutrition education sessions organized. Measured by study administrative data. |
Measured at 6, 12, and 18 months
|
|
Health Care Appointment Fidelity (community health worker-led strategy group)
Lasso di tempo: Measured at 6, 12, and 18 months
|
Percentage of health care visit appointments made. Measured by study administrative data. |
Measured at 6, 12, and 18 months
|
|
Percentage of enrolled participants receiving assigned intervention. Measured by study administrative data. Reach (Participants)
Lasso di tempo: Measured at baseline, 6, 12, and 18 months
|
Percentage of enrolled participants receiving assigned intervention. Measured by study administrative data. |
Measured at baseline, 6, 12, and 18 months
|
|
Reach (Participants)
Lasso di tempo: Measured at baseline
|
The percentage of eligible/screened/contacted participants enrolled. Measured by study data, administrative data. |
Measured at baseline
|
|
Penetrance (Participants)
Lasso di tempo: Measured at baseline, 6, 12, and 18 months
|
Percentage of enrolled participants receiving assigned intervention. Measured by intervention monitoring data. |
Measured at baseline, 6, 12, and 18 months
|
|
Penetrance (Providers)
Lasso di tempo: Measured at baseline, 6, 12, and 18 months
|
Percentage of trained providers delivering protocol-based care. Measured by intervention monitoring data. |
Measured at baseline, 6, 12, and 18 months
|
|
Penetrance (educators)
Lasso di tempo: Measured at baseline, 6, 12, and 18 months
|
Percentage of trained CHWs or providers and health educators delivering health coaching. Measured by intervention monitoring data. |
Measured at baseline, 6, 12, and 18 months
|
|
Sustainability (Churches)
Lasso di tempo: Measured at baseline, 6, 12, and 18 months
|
Percentage of churches continuing the intervention program and individual components. Measured by 6-month post-intervention survey. |
Measured at baseline, 6, 12, and 18 months
|
|
Sustainability (Participants)
Lasso di tempo: Measured at 24 months
|
Percentage of participants maintaining ideal cardiovascular health metrics, healthy lifestyle components, and adherence to medications. Measured by 6-month post-intervention survey and examination. |
Measured at 24 months
|
|
Sustainability Effectiveness Outcome: Differences in mean change of SBP and DBP
Lasso di tempo: Measured at baseline and 24 months
|
Differences in mean change of SBP and DBP from baseline to 24 months (6 months post-intervention) between intervention and control groups |
Measured at baseline and 24 months
|
|
Sustainability Effectiveness Outcome: Difference in the proportion of patients with controlled BP
Lasso di tempo: Measured at baseline and 24 months
|
Difference in the proportion of patients with controlled BP (<130/80 mm Hg) between intervention and control groups at 24 months. |
Measured at baseline and 24 months
|
|
Sustainability of Fidelity
Lasso di tempo: Measured at 24 months
|
A fidelity summary score for key implementation strategy components at 6 months post-intervention (24 months overall). The fidelity summary score is composed of the following key implementation strategy components: proportion of assigned health education sessions attended in all participants, proportion of assigned discussion sessions attended in all participants, proportion of recommended minutes of physical activity completed in all participants, proportion of days per week that fruits/vegetables are eaten as recommended in all participants, proportion of recommended home BP monitoring completed in patients with hypertension, proportion of required provider visits attended in all patients, and proportion of antihypertensive medications taken in patients with hypertension. Fidelity score ranges from zero to six with a higher score indicates greater fidelity. |
Measured at 24 months
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in quality of life
Lasso di tempo: Measured from baseline to 18 months
|
The difference in QoL between the two arms over 18 months. QoL will be assessed using the SF-12 questionnaire. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning. |
Measured from baseline to 18 months
|
Collaboratori e investigatori
Pubblicazioni e link utili
Pubblicazioni generali
- Maroney K, Laurent J, Alvarado F, Gabor A, Bell C, Ferdinand K, He J, Mills KT. Systematic review and meta-analysis of church-based interventions to improve cardiovascular disease risk factors. Am J Med Sci. 2023 Sep;366(3):199-208. doi: 10.1016/j.amjms.2023.05.010. Epub 2023 May 25.
- He J, Bundy JD, Geng S, Tian L, He H, Li X, Ferdinand KC, Anderson AH, Dorans KS, Vasan RS, Mills KT, Chen J. Social, Behavioral, and Metabolic Risk Factors and Racial Disparities in Cardiovascular Disease Mortality in U.S. Adults : An Observational Study. Ann Intern Med. 2023 Sep;176(9):1200-1208. doi: 10.7326/M23-0507. Epub 2023 Aug 15.
- Bundy JD, Mills KT, He H, LaVeist TA, Ferdinand KC, Chen J, He J. Social determinants of health and premature death among adults in the USA from 1999 to 2018: a national cohort study. Lancet Public Health. 2023 Jun;8(6):e422-e431. doi: 10.1016/S2468-2667(23)00081-6.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2022-1081-SPHTM
- R01MD018193 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
The study data sharing plan will comply with all NIH policies for data sharing. Data sharing will be executed through the centralized NIH data repository and will be implemented in a timely manner. The study data, including data from baseline and follow-up visits, will be prepared for transmission to the NHLBI data repository - the Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). The datasets will be submitted to the NHLBI no later than three years after the end of the final participant follow-up or two years after the main paper of the trial has been published, whichever comes first. The NHLBI will review the submitted data prior to release. These data will be free of identifiers that allow identification of individual research participants either directly or through "deductive disclosure." In addition, the investigators will offer, through a publicly accessible website, opportunities for outside investigators to collaborate using complete study data.
Periodo di condivisione IPD
No later than three years after the end of the final participant follow-up or two years after the main paper of the trial has been published, whichever comes first
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .